Guidant to pay Cordis $425 million in patent settlement
This article was originally published in Clinica
Executive Summary
Guidant is facing a $425m hit in the fourth quarter following the preliminary finding of an arbitration panel in its stent patent dispute with Johnson & Johnson subsidiary Cordis. The company will accrue the amount in the second quarter but hopes that the panel will change its mind; the panel's final finding is expected in August.